Search Result

Isoforms Recommended:	TBK1

Results for "

TBK-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Apoptosis (6) Autophagy (6) Biochemical Assay Reagents (1) Caspase (3) CCR (1) CDK (1) CXCR (2) Cyclic GMP-AMP Synthase (2) DNA Stain (1) ERK (1) HBV (1) IFNAR (13) IKK (43) Integrin (1) Interleukin Related (14) Ligands for Target Protein for PROTAC (1) MAP4K (1) MDM-2/p53 (1) Molecular Glues (1) NF-κB (10) NO Synthase (2) p38 MAPK (3) Parasite (1) PARP (2) PD-1/PD-L1 (1) PDK-1 (2) PI3K (1) PIKfyve (1) PKC (2) PROTACs (5) Reactive Oxygen Species (ROS) (1) Reference Standards (3) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Sodium Channel (1) STAT (3) STING (28) Target Protein Ligand-Linker Conjugates (1) TNF Receptor (4) Toll-like Receptor (TLR) (3) ULK (3) Wnt (1)
By Research Areas:	Cancer (36) Cardiovascular Disease (2) Infection (9) Inflammation/Immunology (33) Metabolic Disease (3) Neurological Disease (5)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	CpG ODNs (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112693

H-151 Maximum Cited Publications 138 Publications Verification	STING	Inflammation/Immunology
H-151 is a potent, selective and covalent antagonist of STING that has noteworthy inhibitory activity both in cells and in vivo. H-151 reduces TBK1 phosphorylation and suppresses STING palmitoylation. H-151 can be used for the research of autoinflammatory disease ^[1].

HY-B0713

Amlexanox 20+ Cited Publications AA673; Amoxanox; CHX3673	IKK	Metabolic Disease
Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and *TBK1, and inhibits the IKKε and TBK1* activity determined by MBP phosphorylation with an IC₅₀ of approximately 1-2 μM.

HY-10514

BX795 35+ Cited Publications	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of *PDK1, with an IC₅₀* of 6 nM. BX795 is also a potent and relatively specific inhibitor of *TBK1* and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy ^[1] .

HY-111941

GSK8612 25+ Cited Publications	IKK	Neurological Disease Inflammation/Immunology Cancer
GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC₅₀ of 6.8 for recombinant TBK1 ^[1].

HY-13018

MRT67307 25+ Cited Publications	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 also blocks autophagy in cells .

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active *TBK1* and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to *PD-1* and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity ^[1].

HY-112557

*PROTAC TBK1* degrader-2** 1 Publications Verification	PROTACs IKK	Cancer
PROTAC TBK1 degrader-2 is a Ligands for Target Protein for PROTAC. PROTAC TBK1 degrader-2 is a potent degrader based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) (DC₅₀=15 nM; K_d=4.6 nM) with a maximum efficiency of 96%. PROTAC TBK1 degrader-2 also targets to IkB kinase IKKε (IC₅₀=8.7 nM), with low selectivity over *TBK1* (IC₅₀=1.3 nM) ^[1].

HY-133117

BAY-985 4 Publications Verification	IKK	Cancer
BAY-985, a chemical probe, is a highly potent, orally active and selective ATP-competitive dual inhibitor of *TBK1* and IKKε with IC₅₀s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy ^[1].

HY-116282B

Dextran sulfate sodium salt (MW 16000-24000) 2 Publications Verification DSS (MW 16000-24000); DXS (MW 16000-24000)	Biochemical Assay Reagents STING	Others
Dextran sulfate sodium salt (DSS) (MW 16000-24000) is a polymer of dehydrated glucose with a molecular weight of approximately 16000-24000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 16000-24000) induces STING polymerization and *TBK1* activation ^[1].

HY-160225

ISD sodium 4 Publications Verification	STING Interleukin Related	Inflammation/Immunology
ISD sodium is an interferon-stimulatory DNA, a 45 bp non-CpG double-stranded oligonucleotide derived from the genome of Listeria monocytogenes. ISD sodium potently induces type I interferon production via the *cGAS‑STING‑TBK1‑IRF3* pathway ^[1] .

HY-168034

diABZI-4	STING Integrin NF-κB SARS-CoV	Infection Inflammation/Immunology
diABZI-4 is a STING activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the *TBK1-IRF3* and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms ^[1] .

HY-152237

TBK1-IN-1	IKK	Cancer
TBK1-IN-1 is a potent and selective TANK binding kinase 1 (TBK1) inhibitor with an IC₅₀ value of 22.4 nM. TBK1-IN-1 inhibits TBK1 downstream target genes cxcl10 and ifnβ expression. TBK1-IN-1 has anticancer activity ^[1].

HY-12453

TBK1/IKKε-IN-2 2 Publications Verification	IKK	Inflammation/Immunology
TBK1/IKKε-IN-2 is a dual *TBK1* and IKKε inhibitor.

HY-177338

STING agonist-45	STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
STING agonist-45 is a selective STING agonist (EC₅₀ = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 ⁺ T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases ^[1] .

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via *TBK1* and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis ^[1] .

HY-14682

GSK319347A 1 Publications Verification	IKK	Inflammation/Immunology
GSK319347A is a dual inhibitor of *TBK1* and IKKε with IC₅₀s of 93 nM and 469 nM, respectively. GSK319347A also inhibits IKK2 with an IC₅₀ of 790 nM.

HY-N2616

Vomicine 1 Publications Verification	STING	Inflammation/Immunology
Vomicine modulates *cGAS-STING-TBK1* signaling pathway, and exhibits anti-inflammatory activity. Vomicine is an alkaloid that can be isolated from Strychnos nux-vomica seeds ^[1] .

HY-124652

TBK1/IKKε-IN-4	IKK	Cancer
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective *TBK1* and IKKε inhibitor with IC₅₀ values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR ^[1].

HY-173425

STING-IN-15	STING IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology
STING-IN-15 is an orally active STING inhibitor, with an IC₅₀ of 116 nM against h-STING and an IC₅₀ of 96.3 nM against m-STING. STING-IN-15 inhibits the STING signaling pathway in cells, reduces the secretion of IFN-β and IP-10, downregulates the expression of ISG15, ISG56 and TNF-α, and suppresses the phosphorylation of *TBK1/IRF3*. STING-IN-15 alleviates systemic and renal inflammation induced by STING agonists in mice, reduces tissue damage and the expression of interferon pathway genes, and inhibits spontaneous tissue inflammation in mice. STING-IN-15 can be used for the research of acute kidney injury and autoimmune/inflammatory diseases ^[1].

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via *TBK1* and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis ^[1] .

HY-164288

TDI-6570 TDI-006570	Cyclic GMP-AMP Synthase STING	Neurological Disease Inflammation/Immunology
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC₅₀ of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of *TBK1, blocks double-stranded DNA-induced cGAS* activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases ^[1] .

HY-156449

STING-IN-7	STING IKK	Inflammation/Immunology
STING-IN-7 is a potent STING inhibitor with an IC₅₀ of 11.5 nM. STING-IN-7 can inhibit the phosphorylation of STING, IRF3, and *TBK1*. STING-IN-7 can be used in the research of autoimmune and inflammatory diseases ^[1].

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research ^[1] .

HY-152959

STING agonist-26	STING	Infection Cancer
STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-173414

PROTAC STING degrader-3	PROTACs STING NF-κB	Inflammation/Immunology
PROTAC STING degrader-3 is a STING PROTAC degrader (DC₅₀: 0.62 μM). PROTAC STING degrader-3 induces STING degradation via the ubiquitin-proteasome pathway. PROTAC STING degrader-3 exerts anti-inflammatory effects by inhibiting *STING/TBK1/NF-κB* signaling. PROTAC STING degrader-3 has renal protective effects and can be used in the study of acute kidney injury (AKI) ^[1].

HY-152956

STING agonist-23	STING	Infection Cancer
STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-176334

TBK1 ligand 2	Ligands for Target Protein for PROTAC IKK	Cancer
TBK1 ligand 2 (Compound 1b) is a *TBK1* inhibitor. TBK1 ligand 2 can be used for synthesis of PROTAC TBK1 degrader-2 (HY-112557) ^[1].

HY-176255

TBK1 degrader-4	Molecular Glues Interleukin Related CCR	Inflammation/Immunology
TBK1 degrader-4 (Compound 30) is a molecular glue degrader targeting *TBK1. TBK1* degrader-4 effectively inhibits cyst growth, alleviates inflammation, and reduces the levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1 degrader-4 is promising for research of autosomal dominant polycystic kidney disease (ADPKD) ^[1].

HY-175714

STING agonist-46	STING	Inflammation/Immunology Cancer
STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies ^[1].

HY-162133

MSA-2-Pt	STING Apoptosis IKK IFNAR NF-κB	Cancer
MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a STING agonist. MSA-2-Pt inducing cell death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of *TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 ⁺ and CD8 ⁺ T cells, and induces tumor cell death and apoptosis* in mouse colon carcinoma and melanoma models ^[1].

HY-RS14258

Tbk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Mouse Pre-designed siRNA Set A Tbk1 Mouse Pre-designed siRNA Set A

HY-13018A

MRT67307 hydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 hydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 hydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks autophagy in cells .

HY-U00457

TBK1/IKKε-IN-1	IKK	Cancer
TBK1/IKKε-IN-1 is a dual *TBK1* and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC₅₀s of <100 nM.

HY-178049

UM-259	STING IFNAR Interleukin Related	Neurological Disease Inflammation/Immunology
UM-259 is a STING inhibitor, with an EC₅₀ of 1.50 μM in THP1-Dual cells expressing wild-type STING. UM-259 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of *TBK1* and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-259 can be used for the study of STING-dependent inflammatory and neurological diseases ^[1].

HY-176192

SMU-14a	Toll-like Receptor (TLR) NF-κB p38 MAPK ERK IKK TNF Receptor Interleukin Related	Inflammation/Immunology
SMU-14a is a selective Toll-like receptor 3 (TLR3) inhibitor wirh an IC₅₀ of 0.18 μM. SMU-14a reduces phosphorylation of p65, ERK, and *TBK1* via NF-κB, MAPK, and IRF3 signaling pathways. SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages, downregulates TNF-α in human peripheral blood monocytes and decreases serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used for the research of acute hepatitis ^[1].

HY-173462

TBK1-IN-2	IKK	Cancer
TBK1-IN-2 (Compound A1) is a potent TBK1 inhibitor (IC₅₀: 775 pM). TBK1-IN-2 binds to TBK1 through stable hydrogen bonds and π-π stacking, inhibiting IRF3 phosphorylation. TBK1-IN-2 synergizes with TNF/IFNγ to enhance immune-mediated tumor cell death. TBK1-IN-2 can be used in cancer immunotherapy research ^[1].

HY-N8107

Matairesinol monoglucoside 2 Publications Verification	STING IFNAR HBV	Infection
Matairesinol monoglucoside is a STING activator. Matairesinol monoglucoside modulates the *STING-TBK1-IRF3* signaling axis, promotes STING transcriptional expression, increases *TBK1* and IRF3 phosphorylation. Matairesinol monoglucoside induces IFN-α and IFN-β production, reduces HBV DNA, HBsAg, and HBeAg expression. Matairesinol monoglucoside can be used for the research of hepatitis b virus (hbv) infection ^[1] .

HY-152961

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, *TBK1* and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains ^[1].

HY-RS14259

Tbk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tbk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tbk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tbk1 Rat Pre-designed siRNA Set A Tbk1 Rat Pre-designed siRNA Set A

HY-RS14257

TBK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TBK1 Human Pre-designed siRNA Set A contains three designed siRNAs for TBK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBK1 Human Pre-designed siRNA Set A TBK1 Human Pre-designed siRNA Set A

HY-13018B

MRT67307 dihydrochloride	IKK ULK Autophagy	Inflammation/Immunology Cancer
MRT67307 dihydrochloride is a dual inhibitor of the IKKε and *TBK-1* with IC₅₀s of 160 and 19 nM, respectively ^[1]. MRT67307 dihydrochloride also inhibits *ULK1* and ULK2 with IC₅₀s of 45 and 38 nM, respectively. MRT67307 dihydrochloride also blocks autophagy in cells .

HY-176335

TBK1 ligand 2-C-O-C4-O-C3-O-C-amide	Target Protein Ligand-Linker Conjugates IKK	Cancer
TBK1 ligand 2-C-O-C4-O-C3-O-C-amide is a conjugate of *TBK1* ligand and linker, which can be used in the synthesis of PROTAC TBK1 degrader-2 (HY-112557) ^[1].

HY-B0713R

Amlexanox (Standard) AA673 (Standard); Amoxanox (Standard); CHX3673 (Standard)	Reference Standards IKK	Metabolic Disease
Amlexanox (Standard) is the analytical standard of Amlexanox. This product is intended for research and analytical applications. Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of IKKε and *TBK1, and inhibits the IKKε and TBK1* activity determined by MBP phosphorylation with an IC₅₀ of approximately 1-2 μM.

HY-178915

ITA-5	IKK IFNAR STAT	Inflammation/Immunology
ITA-5 is a *TBK1* inhibitor based on the structure of itaconic acid. can significantly inhibit the secretion of IFN-β. ITA-5 can inhibit the phosphorylation of TBK1, IRF3, and *STAT1*. ITA-5 can be used for research on autoimmune diseases and excessive inflammation ^[1].

HY-178916

ITA-9	IKK IFNAR STAT	Inflammation/Immunology
ITA-9 is a *TBK1* inhibitor based on the structure of itaconic acid. ITA-9 can inhibit the IFN-I signaling pathway. ITA-9 can inhibit the phosphorylation of TBK1, IRF3, and *STAT1*. ITA-9 can be used for research on inflammatory reactions and tissue damage ^[1].

HY-172620

LIB3S0280	IKK Akt Apoptosis PI3K NF-κB CDK Caspase PARP	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
LIB3S0280 is a potent *TBK1* inhibitor with an IC₅₀ value of 493.9 nM. LIB3S0280 exhibits better anticancer effects in pancreatic cancer cell lines with high TBK1 expression. LIB3S0280 inhibits TBK1 downstream signaling pathways, including PI3K/AKT and NF-κB. LIB3S0280 induces G2/M arrest, apoptosis and cellular senescence. LIB3S0280 can be used for pancreatic ductal adenocarcinoma (PDAC) research ^[1].

HY-110341

MRT 68601 hydrochloride	IKK	Cancer
MRT 68601 hydrochloride is a *TBK1* inhibitor with an IC₅₀ value of 6 nM. MRT 68601 hydrochloride inhibits autophagosome formation in lung cancer cells ^[1] .

HY-133117A

(Rac)-BAY-985	IKK	Cancer
(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective *TBK1* inhibitor with an IC₅₀ of 1.5 nM. Antitumor efficacy ^[1].

HY-138931

TBK1/IKKε-IN-6	IKK	Cancer
TBK1/IKKε-IN-6 (example 110) is a *TBK1* and IKKε inhibitor, with IC₅₀ values of <100 nM for both TBK1 and IKKε ^[1].

HY-148206

DMX-129	IKK	Cancer
DMX-129 is an ΙΚΚε and *TBK-1* inhibitor with IC₅₀ values of <30 nM for both TBK1 and IKKε ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via *TBK1* and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis ^[1] .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via *TBK1* and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis ^[1] .

Recombinant Proteins Recommended:

TBK1

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702909

	TBK1 Protein, Human (Active, sf9, GST) NAK	Human	Sf9 insect cells
	TBK1 Protein, Human (Active, sf9, GST) is the recombinant human-derived TBK1, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (1) Rabbit (5)
Reactivity:	Human (6) Mouse (6) Rat (6) Hamster (2)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IP (1) IHC-F (1) WB (6) ELISA (2)
Isotype:	IgG, Kappa (1) IgG (4) IgG1 (1)
Conjugation:	Non-conjugated (6)
Clonality:	Monoclonal (5) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86674

	TBK1 Antibody (YA6366) EC 2.7.11.1; FLJ11330; NAK; NF kappa B activating kinase; NF kB activating kinase; NF-kappa-B-activating kinase; Serine/threonine protein kinase TBK 1; Serine/threonine protein kinase TBK1; Serine/threonine-protein kinase TBK1; T2K; TANK binding kinase 1; TANK-binding kinase 1; TBK 1; TBK1_HUMAN.	WB, IHC-P, IHC-F, IF-Tissue	Human, Rat, Mouse
	TBK1 Antibody (YA6366) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P80519

	TBK1 Antibody (YA662)	WB	Human, Mouse, Rat
	TBK1 Antibody (YA662) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TBK1.

HY-P86381

	TBK1 Antibody (YA6073) TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	TBK1 Antibody (YA6073) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P80910

	TBK1 Antibody (YA040) TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1	WB	Human, Mouse, Rat, Hamster
	TBK1 Antibody (YA040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P80910A

	TBK1 Antibody (YA040)(PBS only) TBK1; NAK; Serine/threonine-protein kinase TBK1; NF-kappa-B-activating kinase; T2K; TANK-binding kinase 1	WB	Human, Mouse, Rat, Hamster
	TBK1 Antibody (YA040) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TBK1.

HY-P87729

	*Phospho-TBK1* (Ser172) Antibody (YA7414)**	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Phospho-TBK1 (Ser172) Antibody (YA7414) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-TBK1 (Ser172).